The company markets and trades a variety of pharmaceutical formulations, wellness products, and FMCG items like coffee and shampoo under its own brands, utilizing third-party contract manufacturing and its own distribution network.
The company lacks a durable moat as evidenced by extremely low net margins of 0.2% and a return on equity of only 1.2%, suggesting no pricing power or brand-based competitive advantage in a fragmented market.
Earnings are largely retained or used to fund working capital for a low-margin trading business; the acquisition of Upender Metaplast has yet to show positive returns, with the subsidiary reporting losses.
The business collapsed as the aggressive revenue growth proved to be an empty pursuit of volume without profit. By 2029, the razor-thin 0.2% margins were entirely consumed by rising interest costs on unsecured loans and the continued bleeding of the Upender Metaplast subsidiary. The working capital cycle stretched to a breaking point, and the lack of an operational audit trail masked a slow-motion liquidation of shareholder value into related-party transactions and uncollectible receivables.
RichFakir rates Fabino Enterprises Ltd's business quality as poor — 19/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Fabino Enterprises Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →